

Biopharma Partnering and Laboratory Services



From Biomarker Discovery to Diagnosis

PGDx partners with researchers and biopharmaceutical companies worldwide to help identify new biomarker targets and accelerate biomarker-driven drug development. Our portfolio of end-to-end tissue and liquid biopsy precision oncology solutions were designed to meet global study needs and are available for in-house testing or through our CRO network.

Services Highlights

- **Research and discovery support:** define complex and emerging biomarkers of response with our highly sensitive and accurate assays
- **Clinical trial assay support:** leverage our CAP/CLIA lab or our global network of CRO partners for your clinical trial needs
- **Global patient access:** distributed kit model enables access to larger patient cohorts via labs around the world
- **CDx co-development:** draw on our international regulatory expertise and deep commercialization experience and reduce risk with our established elio platform

Partner with Confidence

- NGS biomarker solutions developed under design control to comply with US FDA, EU IVDD, and ISO standards
- ISO 15189:2012 and ISO 13485:2016 certified
- Rigorous approach to product development supports a broad range of intended uses to help meet regulatory requirements worldwide
- 510(k) clearance of PGDx elio™ tissue complete
- Experience with multiple precision medicine trials and IDE approval
- Breakthrough device designation for PGDx elio™ plasma resolve
- CAP accredited, CLIA certified laboratory

elio Kitted Solutions: Pan solid tumor profiling and biomarker solutions



PGDx elio tissue complete:
an FDA cleared and CE-IVD marked tumor tissue CGP test



PGDx elio plasma complete:
a liquid biopsy CGP research assay



PGDx elio plasma resolve:
a focused liquid biopsy research assay

Don't see an existing solution that meets your needs?
Contact Partnership@PGDx.com to access additional innovative solutions in our pipeline.

Biopharma Partnering and Laboratory Services



Pharma Partnering Solutions: Agile development across the CDx continuum

We bring years of experience to cutting-edge diagnostics development, with a track record of innovation that ensures we can support you in bringing your oncology breakthrough to market.



Demonstrated performance: leading tissue and liquid biopsy solutions accurately highlight current and emerging biomarkers and genomic signatures, supported by industry-respected publications and global recognition of key opinion leaders




Regulatory and commercial expertise: PGDx offers deep expertise in companion diagnostic development and experience in global biopharma partnerships, with a proven track record of navigating complicated technical and legal frameworks internationally



Consultative partnership model: partnering with PGDx means our joint project team and dedicated service coordinators will support you every step of the way as you navigate the regulatory landscape to approval

Fast-track to CDx with our established platform

- **Build on our established platform:** de-risk operational set-up and avoid lengthy validation timelines with our FDA cleared and CE-IVD marked comprehensive genomic profiling (CGP) kit, elio tissue complete
- **Seamlessly bridge to our global solution:** our expertise in trial transfers and distributed kit model ease the transition from single-site LDTs and enable global patient access




Laboratory Services: Driving innovation from hypothesis to breakthrough solution

Gain unparalleled access to expertise and proprietary novel technologies that have yet to hit the market.



Biomarker discovery:

identify new biomarker targets using retrospective testing services and gain early access to new technological innovations to fuel your research



Expert assay and algorithm development:

we develop customized precision oncology solutions powered by unparalleled computational algorithms to enable accurate and sensitive biomarker detection



Clinical trials:

we offer dynamic solutions to support your research needs with in-house capabilities to support prospective clinical trial testing

1. US Food and Drug Administration: FDA fact sheet: CDRH's approach to tumor profiling next generation sequencing tests.

Learn more about PGDx at [PersonalGenome.com](https://www.personalgenome.com)

For more details about our products, contact Sales@PGDx.com

Personal Genome Diagnostics Inc. | 3600 Boston Street, Suite 10 | Baltimore, Maryland 21224 | (855) 743-9669

©2022 Personal Genome Diagnostics Inc. All Rights Reserved. | MKPR-007-040422 - For Global Marketing Use.

PGDx pharma services menu is comprised of RUO, IUO and IVD products. Refer to services documentation for applicable product intended use. Personal Genome Diagnostics Inc. (PGDx) is a subsidiary of Laboratory Corporation of America Holdings, using the brands Labcorp and Labcorp Oncology.

